Search
for

    Learn

    0 / 0 results
    — no results

    Research

    5 / 15 results
      GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

      research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

      59 citations , August 2021 in “Frontiers in Endocrinology”
      GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

      research Alopecia and Semaglutide: Connecting the Dots for Patient Safety

      4 citations , March 2025 in “Journal of Cosmetic Dermatology”
      Recent evidence suggests a potential link between semaglutide, a GLP-1 receptor agonist used for type 2 diabetes and weight loss, and alopecia. Studies, including a retrospective cohort study by Burke et al. and a scoping review by Tran et al., indicate an increased incidence of hair loss associated with semaglutide. A disproportionality analysis by Godfrey et al. supports these findings, though causality is not confirmed. The rapid weight loss from semaglutide may lead to nutritional deficiencies and endocrine disruptions, contributing to hair loss. The psychosocial impact of alopecia is significant, affecting patient well-being and treatment adherence. There is a critical need for comprehensive clinical trials to confirm these associations and guide safer clinical practices.

    Community Join

    5 / 62 results